← All indications
Uveitis
Inflammation of part or all of the uvea, the middle (vascular) tunic of the eye, and commonly involving the other tunics (sclera and cornea, and the retina). (Dorland, 27th ed)
Subtype terms (4)
More specific conditions that are subtypes of Uveitis in the MeSH hierarchy.
- Panuveitis
13 drugs (11 approved, 2 experimental)
- Uveitis, Intermediate
17 drugs (13 approved, 4 experimental)
- Uveitis, Suppurative
- Uveomeningoencephalitic Syndrome
3 drugs approved
Drugs by status
Approved for this indication (5)
Phase 4 trials (11)
Phase 3 trials (23)
Phase 2 trials (30)
- fingolimod
- aby-035
- b27pd
- apremilast
- golimumab
- tofacitinib
- daclizumab
- denufosol
- esba105
- filgotinib
- leucovorin
- lfg316
- ocriplasmin
- mm-093
- sarilumab
- sotrastaurin
- leflunomide
- abatacept
- everolimus
- tocilizumab
- loteprednol
- ustekinumab
- autologous regulatory t cells
- basiliximab
- minocycline
- anakinra
- interferon gamma-1b
- pp-001
- peys606
- esk-001
Phase 1 trials (6)
Other trials (4)
Organizations
Organization Involved with Phase 4 Indications (31)
- Celgene
- Bausch & Lomb
- Novartis
- Allergan
- Mallinckrodt
- Ocular Therapeutix, Inc.
- Tampa Bay Uveitis Center, LLC
- Ocular Immunology and Uveitis Foundation
- National Eye Institute (NEI)
- University of Pennsylvania
- Duke University
- Hoosier Cancer Research Network
- Johns Hopkins University
- Kyung Hee University
- New England Retina Associates
- Northern California Retina Vitreous Associates
- Oregon Health and Science University
- Seoul National University
- Singapore Eye Research Institute
- Singapore National Eye Centre
- University of California, San Francisco
- University of Cincinnati
- University of Ulsan
- Icahn School of Medicine at Mount Sinai
- University of Campinas
- Tianjin Medical University
- University of Wisconsin
- University of Paris
- Washington University in St. Louis
- Sungkyunkwan University
- +1 more
Organization Involved with Phase 3 Indications (50)
- Abbott
- AbbVie
- Serono
- Sirion Therapeutics
- Bausch Health Companies
- Servier
- Eli Lilly
- Alcon
- Aldeyra Therapeutics, Inc.
- Santen Inc.
- Clearside Biomedical, Inc.
- Eyegate Pharmaceuticals, Inc.
- Lux Biosciences, Inc.
- ORA, Inc.
- Pro Top & Mediking Company Limited
- Xigen SA
- Xoma
- Chulalongkorn University
- University of London
- University of Washington
- King Khaled Eye Specialist Hospital
- Newcastle University
- Northwestern University
- STZ eyetrial
- Sheffield Hallam University
- Sutter Health
- University of Heidelberg
- University of Kansas
- University of Liverpool
- University of Melbourne
- +20 more
Organization Involved with Phase 2 Indications (34)
- Aciont Inc
- PPD
- Bristol-Myers Squibb
- Gilead Sciences
- Merck
- Genentech
- Sanofi
- Can-Fite BioPharma
- Cerimon Pharmaceuticals
- ESBATech AG
- Merrimack Pharmaceuticals
- Forsight Vision4
- The EMMES Corporation
- National Institutes of Health (NIH)
- Cairo University
- Harvard University
- Katholieke Universiteit Leuven
- Ophthalmic Consultants of Boston
- St. Franziskus Hospital
- University of Nebraska
- University of Rochester
- Chongqing Medical University
- University of Utah
- American University of Beirut
- Sun Yat-Sen University
- ZNA Antwerpen
- Kanto Rosai Hospital
- University of Illinois at Chicago
- Institut Cochin
- University of Burgundy
- +4 more
Organization Involved with Phase 1 Indications (11)
Organization Involved with Other Experimental Indications (5)